[{"id":"afe413d7-7e85-457e-9af3-9c556a34d9ac","acronym":"","url":"https://clinicaltrials.gov/study/NCT01396408","created_at":"2021-01-18T05:44:09.814Z","updated_at":"2024-07-02T16:35:17.762Z","phase":"Phase 2","brief_title":"A Phase II Study of Sunitinib or Temsirolimus in Patients With Advanced Rare Tumours","source_id_and_acronym":"NCT01396408","lead_sponsor":"Canadian Cancer Trials Group","biomarkers":" PTEN • STK11 • NF1","pipe":" | ","alterations":" EGFR mutation • PTEN mutation • NF1 mutation • MTOR mutation • AKT1 amplification","tags":["PTEN • STK11 • NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • PTEN mutation • NF1 mutation • MTOR mutation • AKT1 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sunitinib • temsirolimus"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 137","initiation":"Initiation: 02/09/2012","start_date":" 02/09/2012","primary_txt":" Primary completion: 07/06/2015","primary_completion_date":" 07/06/2015","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-02-26"},{"id":"c153810d-16f0-40f8-9439-a64b4b0d79a9","acronym":"","url":"https://clinicaltrials.gov/study/NCT01332279","created_at":"2021-01-18T05:25:50.979Z","updated_at":"2024-07-02T16:35:51.525Z","phase":"Phase 1","brief_title":"Everolimus, Erlotinib Hydrochloride, and Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer Previously Treated With Radiation Therapy","source_id_and_acronym":"NCT01332279","lead_sponsor":"Fox Chase Cancer Center","biomarkers":" EGFR • HIF1A","pipe":" | ","alterations":" EGFR amplification • HIF1A expression • AKT1 amplification","tags":["EGFR • HIF1A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR amplification • HIF1A expression • AKT1 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e erlotinib • everolimus"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 04/01/2011","start_date":" 04/01/2011","primary_txt":" Primary completion: 05/01/2011","primary_completion_date":" 05/01/2011","study_txt":" Completion: 05/01/2011","study_completion_date":" 05/01/2011","last_update_posted":"2023-04-04"},{"id":"652d5ab0-cd46-459c-90cb-214f85150b09","acronym":"","url":"https://clinicaltrials.gov/study/NCT02688881","created_at":"2021-01-18T13:06:49.957Z","updated_at":"2024-07-02T16:36:08.876Z","phase":"Phase 4","brief_title":"Study to Evaluate the Safety and Efficacy of Sirolimus, in Subject With Refractory Solid Tumors","source_id_and_acronym":"NCT02688881","lead_sponsor":"Samsung Medical Center","biomarkers":" PIK3CA • PTEN","pipe":" | ","alterations":" PIK3CA mutation • PIK3CA H1047R • PIK3CA E545K • PIK3CA amplification • PIK3CA E542K • PIK3CA E545 • PIK3CA E542 • AKT1 amplification","tags":["PIK3CA • PTEN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PIK3CA mutation • PIK3CA H1047R • PIK3CA E545K • PIK3CA amplification • PIK3CA E542K • PIK3CA E545 • PIK3CA E542 • AKT1 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sirolimus"],"overall_status":"Completed","enrollment":" Enrollment 6","initiation":"Initiation: 02/05/2017","start_date":" 02/05/2017","primary_txt":" Primary completion: 12/30/2020","primary_completion_date":" 12/30/2020","study_txt":" Completion: 02/24/2021","study_completion_date":" 02/24/2021","last_update_posted":"2022-06-15"}]